The Food and Drug Administration on Thursday changed the prescribing label for Biogen’s Alzheimer’s treatment Aduhelm — narrowing its recommended use to patients with milder forms of the disease.
Biogen and the FDA described the Aduhelm label update as a clarification meant to better reflect data from clinical trials. But changing the label so soon will be seen as the FDA yielding to outside criticism that the drug’s approval — just one month ago — was overly permissive.
Create a display name to comment
This name will appear with your comment